Literature DB >> 20528905

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.

Juan-Manuel Sancho1, Alberto Orfao, Sandra Quijano, Olga García, Carlos Panizo, Elena Pérez-Ceballos, Guillermo Deben, Antonio Salar, Eva González-Barca, Natalia Alonso, Jose-Antonio García-Vela, Javier Capote, Francisco-Javier Peñalver, Mariano Provencio, Jesús Arias, Josefa Plaza, Dolores Caballero, Marta Morado, Evarist Feliu, Josep-Maria Ribera.   

Abstract

BACKGROUND AND AIM: Flow cytometry (FCM) analysis of cerebrospinal fluid (CSF) is more sensitive than conventional cytology (CC) for diagnosis of lymphomatous meningeosis, but the clinical significance of occult central nervous system (CNS) disease (positive FCM with negative CC) remains unknown. PATIENTS AND METHODS: CSF samples from 105 patients with newly diagnosed aggressive lymphomas at high risk of CNS involvement were prospectively studied by both CC and FCM, and results were correlated with cumulative incidence of CNS relapse and overall survival (OS). Patients were divided into three groups: 1) patients without CNS involvement (CC-/FCM-; n=83); 2) individuals with occult CNS disease (FCM+/CC-; n=15); and 3) cases with CNS disease (CC+/FCM+; n=7).
RESULTS: Six cases showed CNS relapse or progression: two in Group 1 (2.4%), two in Group 2 (13%) and two in Group 3 (28.5%) (Group 2 vs. 1, P=0.04; Group 3 vs. 1, P<0.001). Patients from Groups 2 (P=0.05) and 3 (P<0.001) also showed a higher cumulative incidence of CNS relapse than those from Group 1. Significant differences were observed in OS between FCM-/CC- and FCM+/CC+ cases (P=0.02), while patients with occult CNS disease (FCM+/CC-) displayed intermediate OS rates, although differences did not reach statistical significance.
CONCLUSIONS: The presence of occult CNS involvement at diagnosis in patients with NHL at high risk of CNS disease is associated with a higher probability of CNS relapse.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20528905     DOI: 10.1111/j.1600-0609.2010.01478.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  14 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Wyndham H Wilson; Jacoline E C Bromberg; Maryalice Stetler-Stevenson; Seth M Steinberg; Lourdes Martin-Martin; Carmen Muñiz; Juan Manuel Sancho; Maria Dolores Caballero; Marjan A Davidis; Rik A Brooimans; Blanca Sanchez-Gonzalez; Antonio Salar; Eva González-Barca; Jose Maria Ribera; Margaret Shovlin; Armando Filie; Kieron Dunleavy; Thomas Mehrling; Michele Spina; Alberto Orfao
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

Review 3.  [Cytology of cerebrospinal fluid : Standards, importance and modern methods].

Authors:  M Wick; C C Gross; S Isenmann; H Strik
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

4.  Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Authors:  Francisco-Javier Peñalver; Juan-Manuel Sancho; Adolfo de la Fuente; María-Teresa Olave; Alejandro Martín; Carlos Panizo; Elena Pérez; Antonio Salar; Alberto Orfao
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

5.  Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis.

Authors:  D Subirá; M Simó; J Illán; C Serrano; S Castañón; R Gonzalo; J J Granizo; M Martínez-García; M Navarro; J Pardo; J Bruna
Journal:  Clin Exp Metastasis       Date:  2015-03-21       Impact factor: 5.150

Review 6.  Leptomeningeal metastases: a RANO proposal for response criteria.

Authors:  Marc Chamberlain; Larry Junck; Dieta Brandsma; Riccardo Soffietti; Roberta Rudà; Jeffrey Raizer; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Julie Walker; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 7.  Flow Cytometric Detection of Malignant Blasts in Cerebrospinal Fluid: A Biomarker of Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia.

Authors:  Maria Thastrup; Hanne Vibeke Marquart; Kjeld Schmiegelow
Journal:  Biomolecules       Date:  2022-06-09

8.  Central nervous system involvement in AIDS-related lymphomas.

Authors:  Stefan K Barta; Jitesh Joshi; Nicolas Mounier; Xiaonan Xue; Dan Wang; Josep-Maria Ribera; Jose-Tomas Navarro; Christian Hoffmann; Kieron Dunleavy; Richard F Little; Wyndham H Wilson; Michele Spina; Lionel Galicier; Ariela Noy; Joseph A Sparano
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

9.  Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.

Authors:  Cody L Weston; Michael J Glantz; James R Connor
Journal:  Fluids Barriers CNS       Date:  2011-03-03

10.  Prediction of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Using Pretherapeutic [18F]2-Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography/Computed Tomography.

Authors:  Yoo Sung Song; Won Woo Lee; Jong Seok Lee; Sang Eun Kim
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.